Changes

{{Under Construction}}

{{Under Construction}}

<blockquote class='blockedit'>{{Box-round|title=HAEM5 Conversion Notes|This page was converted to the new template on 2023-11-03. The original page can be found at [[HAEM4:Breast Implant-Associated Anaplastic Large Cell Lymphoma]].

<blockquote class='blockedit'>{{Box-round|title=HAEM5 Conversion Notes|This page was converted to the new template on 2023-11-30. The original page can be found at [[HAEM4:Breast Implant-Associated Anaplastic Large Cell Lymphoma]].

}}</blockquote>

}}</blockquote>

==Primary Author(s)*==

==Primary Author(s)*==

__TOC__

__TOC__

==Cancer Category/Type==

==Cancer Category / Type==

* [[Mature T- and NK-cell Neoplasms]]

* [[Mature T- and NK-cell Neoplasms]]

<blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}<ref>{{Cite journal|last=Mw|first=Clemens|last2=Ed|first2=Jacobsen|last3=Sm|first3=Horwitz|date=2019|title=2019 NCCN Consensus Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)|url=https://pubmed.ncbi.nlm.nih.gov/30715173/|language=en|pmid=30715173}}</ref><ref>{{Cite journal|last=Mc|first=Ferrufino-Schmidt|last2=Lj|first2=Medeiros|last3=H|first3=Liu|last4=Mw|first4=Clemens|last5=Kk|first5=Hunt|last6=C|first6=Laurent|last7=J|first7=Lofts|last8=Mb|first8=Amin|last9=S|first9=Ming Chai|date=2018|title=Clinicopathologic Features and Prognostic Impact of Lymph Node Involvement in Patients With Breast Implant-associated Anaplastic Large Cell Lymphoma|url=https://pubmed.ncbi.nlm.nih.gov/29194092/|language=en|pmid=29194092}}</ref><ref name=":0" /></blockquote>

<blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}<ref>{{Cite journal|last=Mw|first=Clemens|last2=Ed|first2=Jacobsen|last3=Sm|first3=Horwitz|date=2019|title=2019 NCCN Consensus Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)|url=https://pubmed.ncbi.nlm.nih.gov/30715173/|language=en|pmid=30715173}}</ref><ref>{{Cite journal|last=Mc|first=Ferrufino-Schmidt|last2=Lj|first2=Medeiros|last3=H|first3=Liu|last4=Mw|first4=Clemens|last5=Kk|first5=Hunt|last6=C|first6=Laurent|last7=J|first7=Lofts|last8=Mb|first8=Amin|last9=S|first9=Ming Chai|date=2018|title=Clinicopathologic Features and Prognostic Impact of Lymph Node Involvement in Patients With Breast Implant-associated Anaplastic Large Cell Lymphoma|url=https://pubmed.ncbi.nlm.nih.gov/29194092/|language=en|pmid=29194092}}</ref><ref name=":0" /></blockquote>

</blockquote>

</blockquote>

==Individual Region Genomic Gain/Loss/LOH==

==Individual Region Genomic Gain / Loss / LOH==

Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Includes aberrations not involving gene fusions. Can include references in the table. Can refer to CGC workgroup tables as linked on the homepage if applicable.'') </span>

Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Includes aberrations not involving gene fusions. Can include references in the table. Can refer to CGC workgroup tables as linked on the homepage if applicable.'') </span>

</blockquote>

</blockquote>

==Gene Mutations (SNV/INDEL)==

==Gene Mutations (SNV / INDEL)==

Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent and common as well either disease defining and/or clinically significant. Can include references in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable; Can also refer to CGC workgroup tables as linked on the homepage if applicable as well as any high impact papers or reviews of gene mutations in this entity.'') </span>

Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent and common as well either disease defining and/or clinically significant. Can include references in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable; Can also refer to CGC workgroup tables as linked on the homepage if applicable as well as any high impact papers or reviews of gene mutations in this entity.'') </span>